TY - JOUR AU - Raza, Afsheen AU - Merhi, Maysaloun AU - Inchakalody, Varghese Philipose AU - Krishnankutty, Roopesh AU - Relecom, Allan AU - Uddin, Shahab AU - Dermime, Said PY - 2020 DA - 2020/03/27 TI - Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy JO - Journal of Translational Medicine SP - 140 VL - 18 IS - 1 AB - Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer. NY-ESO-1, a cancer testis antigen is the most immunogenic antigen to date. The promise of NY-ESO-1 as a candidate for specific immune recognition of cancer comes from its restricted expression in normal adult tissue but frequent occurrence in multiple tumors including melanoma and carcinomas of lung, esophageal, liver, gastric, prostrate, ovarian, and bladder. SN - 1479-5876 UR - https://doi.org/10.1186/s12967-020-02306-y DO - 10.1186/s12967-020-02306-y ID - Raza2020 ER -